FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2293035538> ?p ?o ?g. }

• W2293035538 abstract "Abstract Background Preclinical models have suggested that HDAC and mTOR inhibitors have synergistic antineoplastic activity in Hodgkin lymphoma and other cancers by reducing the activity of AKT, mTOR and HDAC. Methods We designed a phase I study to determine the safety of the mTOR inhibitor sirolimus (1mg-5mg PO daily q 28 days) and HDAC inhibitor vorinostat (100mg-400mg PO daily q 28 days) in advanced cancers with an expansion cohort at the recommended phase 2 dose (RP2D) of sirolimus 4mg and vorinostat 300mg for patients with refractory classical Hodgkin lymphoma. The expansion cohort included optional pre- and post-treatment tumor biopsies, peripheral blood mononuclear cells (PBMCs), plasma/serum collections for pharmacodynamic (PD) and pharmacokinetic (PK) endpoints. Results A total of 16 patients (men, n=8; women, n=8), median age 33 years, median of 6.5 prior therapies (including autologous SCT [n=15], autologous and allogeneic SCT [n=4]) were enrolled in dose escalation (n=1) or RP2D (n=15) cohorts. At the median follow-up of 3.2 months, 15 (94%) patients demonstrated decreased FDG uptake including 2 CRs (13%) and 5 PRs (31%) using CHESON criteria, with a total CR+PR rate of 44%. The median reduction of tumor was -27% (-100% to +20%, Figure). The estimated median time-to-treatment failure has not been reached and 63% of the patients continued on therapy with further improvement in their level of disease response. Major grade 3-4 treatment-related toxicities included grade 3 thrombocytopenia (4 patients, 25%), grade 4 thrombocytopenia (6, 38%), grade 3 anemia (1, 6%), febrile neutropenia (1, 6%) and led to treatment interruptions and/or dose modifications in 10 (63%) patients. Five (31%) patients had archival tissue available for targeted next-generation sequencing and one patient had a loss of TSC2, an abnormality that putatively activates mTOR. This patient has had a continuing response to therapy (-56%) for 8.4+ months. PD studies in pre- and post-treatment tumor biopsies, PBMCs and plasma as well as PK analysis continue. Conclusion The combination of sirolimus and vorinostat is well tolerated with encouraging activity in very heavily pretreated patients with Hodgkin lymphoma refractory to standard therapies. Enrollment continues. Disclosures: Off Label Use: sirolimus - mTOR inhibitor vorinostat - HDAC inhibitor." @default.
• W2293035538 created "2016-06-24" @default.
• W2293035538 creator A5021068642 @default.
• W2293035538 creator A5021496101 @default.
• W2293035538 creator A5026095888 @default.
• W2293035538 creator A5028677309 @default.
• W2293035538 creator A5029563022 @default.
• W2293035538 creator A5030868239 @default.
• W2293035538 creator A5036211173 @default.
• W2293035538 creator A5037784199 @default.
• W2293035538 creator A5043675371 @default.
• W2293035538 creator A5053481267 @default.
• W2293035538 creator A5055885795 @default.
• W2293035538 creator A5069777765 @default.
• W2293035538 creator A5071800834 @default.
• W2293035538 creator A5074743570 @default.
• W2293035538 creator A5076385474 @default.
• W2293035538 creator A5076426660 @default.
• W2293035538 creator A5085712310 @default.
• W2293035538 creator A5090618436 @default.
• W2293035538 date "2013-11-15" @default.
• W2293035538 modified "2023-10-18" @default.
• W2293035538 title "Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients" @default.
• W2293035538 doi "https://doi.org/10.1182/blood.v122.21.3048.3048" @default.
• W2293035538 hasPublicationYear "2013" @default.
• W2293035538 type Work @default.
• W2293035538 sameAs 2293035538 @default.
• W2293035538 citedByCount "1" @default.
• W2293035538 countsByYear W22930355382021 @default.
• W2293035538 crossrefType "journal-article" @default.
• W2293035538 hasAuthorship W2293035538A5021068642 @default.
• W2293035538 hasAuthorship W2293035538A5021496101 @default.
• W2293035538 hasAuthorship W2293035538A5026095888 @default.
• W2293035538 hasAuthorship W2293035538A5028677309 @default.
• W2293035538 hasAuthorship W2293035538A5029563022 @default.
• W2293035538 hasAuthorship W2293035538A5030868239 @default.
• W2293035538 hasAuthorship W2293035538A5036211173 @default.
• W2293035538 hasAuthorship W2293035538A5037784199 @default.
• W2293035538 hasAuthorship W2293035538A5043675371 @default.
• W2293035538 hasAuthorship W2293035538A5053481267 @default.
• W2293035538 hasAuthorship W2293035538A5055885795 @default.
• W2293035538 hasAuthorship W2293035538A5069777765 @default.
• W2293035538 hasAuthorship W2293035538A5071800834 @default.
• W2293035538 hasAuthorship W2293035538A5074743570 @default.
• W2293035538 hasAuthorship W2293035538A5076385474 @default.
• W2293035538 hasAuthorship W2293035538A5076426660 @default.
• W2293035538 hasAuthorship W2293035538A5085712310 @default.
• W2293035538 hasAuthorship W2293035538A5090618436 @default.
• W2293035538 hasConcept C104317684 @default.
• W2293035538 hasConcept C111113717 @default.
• W2293035538 hasConcept C112705442 @default.
• W2293035538 hasConcept C121332964 @default.
• W2293035538 hasConcept C126322002 @default.
• W2293035538 hasConcept C142424586 @default.
• W2293035538 hasConcept C143998085 @default.
• W2293035538 hasConcept C185592680 @default.
• W2293035538 hasConcept C2776262904 @default.
• W2293035538 hasConcept C2777921159 @default.
• W2293035538 hasConcept C2778305200 @default.
• W2293035538 hasConcept C2779338263 @default.
• W2293035538 hasConcept C55493867 @default.
• W2293035538 hasConcept C64927066 @default.
• W2293035538 hasConcept C71924100 @default.
• W2293035538 hasConcept C72563966 @default.
• W2293035538 hasConcept C87355193 @default.
• W2293035538 hasConcept C90924648 @default.
• W2293035538 hasConcept C98274493 @default.
• W2293035538 hasConceptScore W2293035538C104317684 @default.
• W2293035538 hasConceptScore W2293035538C111113717 @default.
• W2293035538 hasConceptScore W2293035538C112705442 @default.
• W2293035538 hasConceptScore W2293035538C121332964 @default.
• W2293035538 hasConceptScore W2293035538C126322002 @default.
• W2293035538 hasConceptScore W2293035538C142424586 @default.
• W2293035538 hasConceptScore W2293035538C143998085 @default.
• W2293035538 hasConceptScore W2293035538C185592680 @default.
• W2293035538 hasConceptScore W2293035538C2776262904 @default.
• W2293035538 hasConceptScore W2293035538C2777921159 @default.
• W2293035538 hasConceptScore W2293035538C2778305200 @default.
• W2293035538 hasConceptScore W2293035538C2779338263 @default.
• W2293035538 hasConceptScore W2293035538C55493867 @default.
• W2293035538 hasConceptScore W2293035538C64927066 @default.
• W2293035538 hasConceptScore W2293035538C71924100 @default.
• W2293035538 hasConceptScore W2293035538C72563966 @default.
• W2293035538 hasConceptScore W2293035538C87355193 @default.
• W2293035538 hasConceptScore W2293035538C90924648 @default.
• W2293035538 hasConceptScore W2293035538C98274493 @default.
• W2293035538 hasLocation W22930355381 @default.
• W2293035538 hasOpenAccess W2293035538 @default.
• W2293035538 hasPrimaryLocation W22930355381 @default.
• W2293035538 hasRelatedWork W1515065013 @default.
• W2293035538 hasRelatedWork W2010901292 @default.
• W2293035538 hasRelatedWork W2313574080 @default.
• W2293035538 hasRelatedWork W2467225938 @default.
• W2293035538 hasRelatedWork W2546550353 @default.
• W2293035538 hasRelatedWork W2550925711 @default.
• W2293035538 hasRelatedWork W2553566409 @default.
• W2293035538 hasRelatedWork W2557504094 @default.
• W2293035538 hasRelatedWork W2558650006 @default.
• W2293035538 hasRelatedWork W2562046766 @default.
• W2293035538 hasRelatedWork W2562731214 @default.

• next